- Home
- VRNS vs LIVN Comparison
VRNS vs LIVN Comparison
Compare VRNS & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | LIVN |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.5B |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VRNS | LIVN |
|---|---|---|
| Price | $45.86 | $81.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 7 |
| Target Price | $42.75 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 1.9M | 545.6K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | ★ $270,288,000.00 | N/A |
| Revenue This Year | $18.87 | $9.79 |
| Revenue Next Year | $17.77 | $6.63 |
| P/E Ratio | ★ N/A | $201.45 |
| Revenue Growth | ★ 24.35 | N/A |
| 52 Week Low | $19.70 | $41.02 |
| 52 Week High | $63.90 | $85.27 |
Technical Indicators
Market Signals| Indicator | VRNS | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 60.94 | 55.86 |
| Support Level | $31.28 | $61.63 |
| Resistance Level | $49.54 | $85.27 |
| Average True Range (ATR) | 2.24 | 2.26 |
| MACD | -0.55 | -0.38 |
| Stochastic Oscillator | 34.92 | 70.95 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About LIVN LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.